8月17日，奥洛兹美医疗盘中上涨5.05%，报103.64美元/股，成交额8389.84万美元。
消息面上，公司8月7日发布的Q2财报大幅超出市场预期：调整后每股收益2.28美元，超预期约24%；营收4.81亿美元，超预期约18%。同时公司将全年指引上调至调整后EPS 8.65-9.00美元（此前7.75-8.25美元），营收上调至18.35-19.10亿美元。财报发布后，Leerink Partners将评级上调至"跑赢大盘"，目标价从83美元大幅提升至110美元；摩根士丹利维持"增持"评级，目标价从93美元上调至105美元。此外，公司近期密集签署合作协议，先后与GSK、Incyte、Vertex等巨头就ENHANZE及Hypercon技术达成授权，持续拓宽收入来源。强劲业绩与估值重评共同推动股价延续上行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.